Study Identifies Risk Factors for Urethral Recurrence After Radical Cystectomy
Study findings support surveillance for urethral recurrence after radical cystectomy.
Diagnosis & Disease Information
Olaparib Has Limited Antitumor Activity Against Some HRR Genes in mCRPC
Olaparib had greater antitumor activity against BRCA1/2-mutant metastatic castration-resistant prostate cancer (mCRPC).
No Association Between ADT and SARS-CoV-2 Infection in Prostate Cancer
The aim of this study was to determine whether androgen deprivation therapy (ADT) affords protection against SARS-CoV-2 infection in a population of patients with prostate cancer.
Primary EV-301 Results Confirm Enfortumab Vedotin’s Superiority Over Chemotherapy in Advanced Urothelial Carcinoma
Powles et al present the primary results from the phase 3 EV-301 trial in advanced urothelial carcinoma.
HIF-2α Inhibitor/Cabozantinib Doublet Active in Previously Treated Advanced ccRCC
Choueiri et al tested the efficacy of the investigational hypoxia-inducible factor 2α (HIF-2α) inhibitor in combination with cabozantinib.
Real-World Data: Cabozantinib Used More Commonly Than Other TKIs After Checkpoint Inhibition in mRCC
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
Final TITAN Analysis Confirms Superior OS Benefit With Apalutamide and ADT Versus ADT Alone
The final analysis of the phase 3 TITAN trial included nearly 4 years of follow-up.
Nivolumab, Docetaxel, and ADT Triplet Confers Antitumor Activity in mCRPC Regardless of Prior NAT Use
Karim Fizazi, MD, PhD, presents final analysis results from arm B of the phase 2 CheckMate 9KD trial.
Reduced PSA Screening Correlates With Uptick in Metastatic Prostate Cancer Presentation at Diagnosis
Sharma et al investigated whether reductions in prostate-specific antigen (PSA) screening were responsible for increased metastatic prostate cancer diagnoses in the United States.
Nivolumab/Cabozantinib Prolongs OS in Advanced RCC With Sarcomatoid Features
CheckMate 9ER investigators assessed the efficacy of combination nivolumab and cabozantinib in the front-line sarcomatoid renal cell carcinoma (RCC) setting in an extended analysis.
- Loading...
Loading...
Next post in ASCO GU 2021
Loading... 
Loading...